Back to List View Graph View

Infliximab

Infliximab is a therapeutic monoclonal antibody used in the treatment of immune-mediated inflammatory diseases.

Where the papers sit

15 papers from the last 6 months study infliximab directly · updated from PubMed 8 Nov 2026

Those 15 are all about one subject.

  • Biologic Therapy in IBD

    Biologic treatment in inflammatory bowel disease is moving toward normalized biosimilar use and more individualized dosing. Persistence, pharmacokinetic modeling, therapeutic drug monitoring, and assay standardization recur as tools for optimizing infliximab exposure. Comparative safety work examines heart failure, granulomatous reactions, and risks across adult and pediatric populations, while evidence gaps remain in children. Economic analyses and switching policies increasingly frame biosimilars as sustainable alternatives, although long-term outcomes and benefit-risk trade-offs remain under study.

    15 papers

NEW DIRECTION

Infliximab is reported as a trigger of concurrent sarcoid-like inflammation and haemophagocytic lymphohistiocytosis

Multisystem sarcoidosis with drug-associated sarcoid-like reaction and secondary haemophagocytic lymphohistiocytosis was the subject of this report. Whereas the other papers use infliximab as a treatment, comparator, or analyte, this study found that infliximab exposure preceded concurrent sarcoid-like inflammation and hyperinflammation, which improved after the drug was stopped and immunosuppressive therapy was given. This assigns infliximab a pathogenic role outside the therapeutic and analytical categories otherwise represented in the set 42618309Aug.

Papers

The 15 papers from the last 6 months that study infliximab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Biologic Therapy in IBD (15)
  1. Treatment patterns and determinants of persistence with advanced therapies in adults with newly diagnosed Crohn's disease: an interim analysis of an inception cohort registry study (iCREST-CD). Journal of Crohn's & colitis · 7 Nov 2026 PMID 42998010
  2. Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
  3. Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization. Revista espanola de enfermedades digestivas · 26 Oct 2026 PMID 42929266
  4. Crohn's disease unmasks pulmonary sarcoidosis on biologic screening: dual granulomatous pathology responsive to infliximab. BMJ case reports · 28 Sept 2026 PMID 42805621
  5. Randomised treatment of acute pancreatitis with infliximab: protocol for a double-blind, placebo-controlled, multi-centre, adaptive, phase 2 superiority trial (RAPID-I). BMJ open · 18 Sept 2026 PMID 42760074
  6. Sex Differences in Growth Recovery among Children with Crohn's Disease. Gut and liver · 31 Aug 2026 PMID 42670695
  7. Bridging the Gap Between Chemiluminescence Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry for Infliximab Monitoring: Method Validation and Clinical Comparability Study. Journal of separation science · 29 Aug 2026 PMID 42667246
  8. Infliximab-associated sarcoid-like reaction and haemophagocytic lymphohistiocytosis in multisystem sarcoidosis. BMJ case reports · 19 Aug 2026 PMID 42618309
  9. Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
  10. Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing. PloS one · 24 Jul 2026 PMID 42497217
  11. Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
  12. Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183
  13. Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database. Proceedings (Baylor University. Medical Center) · 10 Jun 2026 PMID 42269048
  14. Systematic development and optimization of a cIEF method for the charge variants analysis of moderately basic to basic monoclonal antibodies using the Analytical Quality by Design strategy. Journal of pharmaceutical and biomedical analysis · 26 May 2026 PMID 42190399
  15. The Longer-Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population-Based Study. Pharmacoepidemiology and drug safety · 20 May 2026 PMID 42157439

By study type

Clinical trials (1)
  1. Randomised treatment of acute pancreatitis with infliximab: protocol for a double-blind, placebo-controlled, multi-centre, adaptive, phase 2 superiority trial (RAPID-I). BMJ open · 18 Sept 2026 PMID 42760074
Observational studies and case reports (7)
  1. Treatment patterns and determinants of persistence with advanced therapies in adults with newly diagnosed Crohn's disease: an interim analysis of an inception cohort registry study (iCREST-CD). Journal of Crohn's & colitis · 7 Nov 2026 PMID 42998010
  2. Crohn's disease unmasks pulmonary sarcoidosis on biologic screening: dual granulomatous pathology responsive to infliximab. BMJ case reports · 28 Sept 2026 PMID 42805621
  3. Sex Differences in Growth Recovery among Children with Crohn's Disease. Gut and liver · 31 Aug 2026 PMID 42670695
  4. Infliximab-associated sarcoid-like reaction and haemophagocytic lymphohistiocytosis in multisystem sarcoidosis. BMJ case reports · 19 Aug 2026 PMID 42618309
  5. Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing. PloS one · 24 Jul 2026 PMID 42497217
  6. Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database. Proceedings (Baylor University. Medical Center) · 10 Jun 2026 PMID 42269048
  7. The Longer-Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population-Based Study. Pharmacoepidemiology and drug safety · 20 May 2026 PMID 42157439
Human data, design not indexed (3)
  1. Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
  2. Bridging the Gap Between Chemiluminescence Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry for Infliximab Monitoring: Method Validation and Clinical Comparability Study. Journal of separation science · 29 Aug 2026 PMID 42667246
  3. Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
Preclinical: animal, cell and lab studies (2)
  1. Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
  2. Systematic development and optimization of a cIEF method for the charge variants analysis of moderately basic to basic monoclonal antibodies using the Analytical Quality by Design strategy. Journal of pharmaceutical and biomedical analysis · 26 May 2026 PMID 42190399
Unclassified: not yet indexed with MeSH (2)
  1. Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization. Revista espanola de enfermedades digestivas · 26 Oct 2026 PMID 42929266
  2. Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183